Literature DB >> 21700369

New insights into the structural requirements for pro-apoptotic agents based on 2,4-diaminoquinazoline, 2,4-diaminopyrido[2,3-d]pyrimidine and 2,4-diaminopyrimidine derivatives.

María Font1, Álvaro González, Juan Antonio Palop, Carmen Sanmartín.   

Abstract

As a continuation of our work on new anti-tumoral derivatives with selective pro-apoptotic activity in cancer cells, we describe the synthesis and the preliminary evaluation of the cytotoxic and pro-apoptotic activities of a series of pyrimidin-2,4-diamine derivatives that are structurally related to quinazolin-2,4-diamine and pyrido[2,3-d]pyrimidin-2,4-diamine derivatives. We also describe the structure-activity relationship studies carried out on four series' of quinazolin-2,4-diamine, 2-(alkylsulfanyl)-N-alkyl- and 2-(alkylsulfanyl)-N-alkylarylpyrido[2,3-d]pyrimidine and pyrimidin-2,4-diamine derivatives. The proposed preliminary pharmacophore consists of a flat heterocyclic ring, preferably a pyrido[2,3-d]pyrimidine, with two equivalent alkylarylamine chains, preferably N-benzyl- or N-ethylphenylamine, located in positions 2 and 4 of the ring, and with a preferred ALogP in the range 4.5-5.5. The nitrogen present in the central ring can act as hydrogen bond acceptors (HBA) whereas the amino group in the 4-position can act as a donor (HBD) or an HBA and the amino group in the 2-position can act as an HBD. On the basis of the analyzed structural profiles, different mechanisms of action can be suggested for the quinazolin-2,4-diamine, the 2-(alkylsulfanyl)-N-alkylpyrido[2,3-d]pyrimidin-4-amine and the pyrido[2,3-d]pyrimidin-2,4-diamine derivatives.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21700369     DOI: 10.1016/j.ejmech.2011.05.060

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  7 in total

1.  Synthesis and SAR studies of novel 6,7,8-substituted 4-substituted benzyloxyquinolin-2(1H)-one derivatives for anticancer activity.

Authors:  Yi-Fong Chen; Yi-Chien Lin; Susan L Morris-Natschke; Chen-Fang Wei; Ting-Chen Shen; Hui-Yi Lin; Mei-Hua Hsu; Li-Chen Chou; Yu Zhao; Sheng-Chu Kuo; Kuo-Hsiung Lee; Li-Jiau Huang
Journal:  Br J Pharmacol       Date:  2015-01-13       Impact factor: 8.739

2.  Unconventional N-H…N Hydrogen Bonds Involving Proline Backbone Nitrogen in Protein Structures.

Authors:  R N V Krishna Deepak; Ramasubbu Sankararamakrishnan
Journal:  Biophys J       Date:  2016-05-10       Impact factor: 4.033

3.  An efficient and environmentally sustainable domino protocol for the synthesis of structurally diverse spiroannulated pyrimidophenazines using erbium doped TiO2 nanoparticles as a recyclable and reusable heterogeneous acid catalyst.

Authors:  Kanchan Verma; Yogesh Kumar Tailor; Sarita Khandelwal; Monu Agarwal; Esha Rushell; Yogita Kumari; Kamlendra Awasthi; Mahendra Kumar
Journal:  RSC Adv       Date:  2018-08-28       Impact factor: 4.036

Review 4.  An insight into the therapeutic potential of quinazoline derivatives as anticancer agents.

Authors:  Irshad Ahmad
Journal:  Medchemcomm       Date:  2017-04-07       Impact factor: 3.597

5.  Synthesis and cytotoxic evaluation of some novel 3-[2-(2-phenyl-thiazol-4-yl)-ethyl]-3H-pyrido[2,3-d]pyrimidin-4-one derivatives.

Authors:  Marzieh Rahmani Khajouei; Ghadamali Khodarahmi; Aram Ghaderi
Journal:  Res Pharm Sci       Date:  2021-08-19

6.  Antiproliferative Activity of (-)-Isopulegol-based 1,3-Oxazine, 1,3-Thiazine and 2,4-Diaminopyrimidine Derivatives.

Authors:  Fatima Z Bamou; Tam M Le; Bizhar A Tayeb; Seyyed A S Tahaei; Renáta Minorics; István Zupkó; Zsolt Szakonyi
Journal:  ChemistryOpen       Date:  2022-10       Impact factor: 2.630

7.  Synthesis, Antitumor Evaluation and Molecular Docking of New Morpholine Based Heterocycles.

Authors:  Zeinab A Muhammad; Mastoura M Edrees; Rasha A M Faty; Sobhi M Gomha; Seham S Alterary; Yahia N Mabkhot
Journal:  Molecules       Date:  2017-07-20       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.